Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation

Richard L. Momparler, Youssef Idaghdhour, Victor E. Marquez, Louise F. Momparler

Research output: Contribution to journalArticle

Abstract

DNA methylation and histone methylation are both involved in epigenetic regulation of gene expression and their dysregulation can play an important role in leukemogenesis. Aberrant DNA methylation has been reported to silence the expression of tumor suppressor genes in leukemia. Overexpression of the histone methyltransferase, EZH2, a subunit of the polycomb group repressive complex 2 (PRC2), was observed to promote oncogenesis. This is due to aberrant gene silencing by the trimethylation of histone H3 lysine 27 (H3K27me3) by EZH2. Since both these epigenetic silencing events are reversible, they are interesting targets for chemotherapeutic intervention by using an inhibitor of DNA methylation, such as 5-aza-2'-deoxcytidine (5-AZA-CdR), and 3-deazaneplanocin-A (DZNep), an inhibitor of the EZH2. Human HL-60 and murine L1210 leukemic cells exposed in vitro to 5-AZA-CdR and DZNep in combination showed a synergistic loss of clonogenicity in a colony assay as compared to each agent alone. This positive chemotherapeutic interaction was also observed in mice with L1210 leukemia. Quantitative PCR showed that the combination also produced a remarkable synergistic activation of the tumor suppressor genes, CDKN1A and FBXO32. Microarray analysis showed that 5-AZA-CdR plus DZNep produced a synergistic activation of >150 genes. Our results indicate that 5-AZA-CdR plus DZNep can reactivate target genes that are silenced by two distinct epigenetic mechanisms leading to a loss of the proliferative potential of leukemic cells.

Original languageEnglish (US)
Pages (from-to)1049-1054
Number of pages6
JournalLeukemia Research
Volume36
Issue number8
DOIs
StatePublished - Aug 1 2012

Fingerprint

DNA Methylation
Histones
Methylation
Epigenomics
Tumor Suppressor Genes
Polycomb Repressive Complex 2
Leukemia L1210
Gene Expression Regulation
Gene Silencing
Microarray Analysis
Genes
Lysine
Carcinogenesis
Leukemia
Polymerase Chain Reaction
3-deazaneplanocin

Keywords

  • 3-Deazaplanocin-A
  • 5-Aza-2'-deoxycytidine
  • Chemotherapy
  • DNA methylation
  • Gene expression
  • Histone methylation
  • Mouse model

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation. / Momparler, Richard L.; Idaghdhour, Youssef; Marquez, Victor E.; Momparler, Louise F.

In: Leukemia Research, Vol. 36, No. 8, 01.08.2012, p. 1049-1054.

Research output: Contribution to journalArticle

Momparler, Richard L. ; Idaghdhour, Youssef ; Marquez, Victor E. ; Momparler, Louise F. / Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation. In: Leukemia Research. 2012 ; Vol. 36, No. 8. pp. 1049-1054.
@article{cc9ae5a347e542d3842a68365a653227,
title = "Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation",
abstract = "DNA methylation and histone methylation are both involved in epigenetic regulation of gene expression and their dysregulation can play an important role in leukemogenesis. Aberrant DNA methylation has been reported to silence the expression of tumor suppressor genes in leukemia. Overexpression of the histone methyltransferase, EZH2, a subunit of the polycomb group repressive complex 2 (PRC2), was observed to promote oncogenesis. This is due to aberrant gene silencing by the trimethylation of histone H3 lysine 27 (H3K27me3) by EZH2. Since both these epigenetic silencing events are reversible, they are interesting targets for chemotherapeutic intervention by using an inhibitor of DNA methylation, such as 5-aza-2'-deoxcytidine (5-AZA-CdR), and 3-deazaneplanocin-A (DZNep), an inhibitor of the EZH2. Human HL-60 and murine L1210 leukemic cells exposed in vitro to 5-AZA-CdR and DZNep in combination showed a synergistic loss of clonogenicity in a colony assay as compared to each agent alone. This positive chemotherapeutic interaction was also observed in mice with L1210 leukemia. Quantitative PCR showed that the combination also produced a remarkable synergistic activation of the tumor suppressor genes, CDKN1A and FBXO32. Microarray analysis showed that 5-AZA-CdR plus DZNep produced a synergistic activation of >150 genes. Our results indicate that 5-AZA-CdR plus DZNep can reactivate target genes that are silenced by two distinct epigenetic mechanisms leading to a loss of the proliferative potential of leukemic cells.",
keywords = "3-Deazaplanocin-A, 5-Aza-2'-deoxycytidine, Chemotherapy, DNA methylation, Gene expression, Histone methylation, Mouse model",
author = "Momparler, {Richard L.} and Youssef Idaghdhour and Marquez, {Victor E.} and Momparler, {Louise F.}",
year = "2012",
month = "8",
day = "1",
doi = "10.1016/j.leukres.2012.03.001",
language = "English (US)",
volume = "36",
pages = "1049--1054",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation

AU - Momparler, Richard L.

AU - Idaghdhour, Youssef

AU - Marquez, Victor E.

AU - Momparler, Louise F.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - DNA methylation and histone methylation are both involved in epigenetic regulation of gene expression and their dysregulation can play an important role in leukemogenesis. Aberrant DNA methylation has been reported to silence the expression of tumor suppressor genes in leukemia. Overexpression of the histone methyltransferase, EZH2, a subunit of the polycomb group repressive complex 2 (PRC2), was observed to promote oncogenesis. This is due to aberrant gene silencing by the trimethylation of histone H3 lysine 27 (H3K27me3) by EZH2. Since both these epigenetic silencing events are reversible, they are interesting targets for chemotherapeutic intervention by using an inhibitor of DNA methylation, such as 5-aza-2'-deoxcytidine (5-AZA-CdR), and 3-deazaneplanocin-A (DZNep), an inhibitor of the EZH2. Human HL-60 and murine L1210 leukemic cells exposed in vitro to 5-AZA-CdR and DZNep in combination showed a synergistic loss of clonogenicity in a colony assay as compared to each agent alone. This positive chemotherapeutic interaction was also observed in mice with L1210 leukemia. Quantitative PCR showed that the combination also produced a remarkable synergistic activation of the tumor suppressor genes, CDKN1A and FBXO32. Microarray analysis showed that 5-AZA-CdR plus DZNep produced a synergistic activation of >150 genes. Our results indicate that 5-AZA-CdR plus DZNep can reactivate target genes that are silenced by two distinct epigenetic mechanisms leading to a loss of the proliferative potential of leukemic cells.

AB - DNA methylation and histone methylation are both involved in epigenetic regulation of gene expression and their dysregulation can play an important role in leukemogenesis. Aberrant DNA methylation has been reported to silence the expression of tumor suppressor genes in leukemia. Overexpression of the histone methyltransferase, EZH2, a subunit of the polycomb group repressive complex 2 (PRC2), was observed to promote oncogenesis. This is due to aberrant gene silencing by the trimethylation of histone H3 lysine 27 (H3K27me3) by EZH2. Since both these epigenetic silencing events are reversible, they are interesting targets for chemotherapeutic intervention by using an inhibitor of DNA methylation, such as 5-aza-2'-deoxcytidine (5-AZA-CdR), and 3-deazaneplanocin-A (DZNep), an inhibitor of the EZH2. Human HL-60 and murine L1210 leukemic cells exposed in vitro to 5-AZA-CdR and DZNep in combination showed a synergistic loss of clonogenicity in a colony assay as compared to each agent alone. This positive chemotherapeutic interaction was also observed in mice with L1210 leukemia. Quantitative PCR showed that the combination also produced a remarkable synergistic activation of the tumor suppressor genes, CDKN1A and FBXO32. Microarray analysis showed that 5-AZA-CdR plus DZNep produced a synergistic activation of >150 genes. Our results indicate that 5-AZA-CdR plus DZNep can reactivate target genes that are silenced by two distinct epigenetic mechanisms leading to a loss of the proliferative potential of leukemic cells.

KW - 3-Deazaplanocin-A

KW - 5-Aza-2'-deoxycytidine

KW - Chemotherapy

KW - DNA methylation

KW - Gene expression

KW - Histone methylation

KW - Mouse model

UR - http://www.scopus.com/inward/record.url?scp=84862556419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862556419&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2012.03.001

DO - 10.1016/j.leukres.2012.03.001

M3 - Article

C2 - 22472464

AN - SCOPUS:84862556419

VL - 36

SP - 1049

EP - 1054

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 8

ER -